Why ECPC Matters
The challenge of access to medicines is of crucial importance to millions of Europeans affected by cancer every year. Whilst no one country is immune to access issues, some regions and countries in Europe face greater difficulties than others. Several factors have an impact on access to medicines, from regulatory standards to funding systems and the varying nature of healthcare systems across Europe – all adding to inequalities across Europe. The European Parliament adopted a report, on its own initiative, on the ‘Options for Improving Access to Medicines’ – presenting an opportunity for the European Parliament to take a proactive stance on the issue of access to medicines. It makes several calls for action aimed at EU and Member State institutions to address the most urgent challenges when it comes to access to medicines, stressing the added value of European cooperation.
ECPC AGM 2020
Today the European Cancer Patient Coalition launched “Personalised Medicine: A Guide for Patients” – a booklet to address the opportunities and challenges that personalised medicine provides, so that the needs of cancer patients across Europe are met.
This patient toolkit has been developed by ecancer together with the European Cancer Patient Coalition to provide patients with a comprehensive resource on biosimilar medicines.
It includes six interactive modules which can help you to make informed decisions for your treatment.
Learn what a biosimilar medicine is and how you can be involved in decisions about your cancer treatment.
The European Cancer Patient Coalition supports the management, dissemination and exploitation of the ImmunoSABR project.
This programme is funded by the Horizon 2020 Research and Innovation Programme.
ECPC is also organising sessions in regards to patient consultation so the ImmunoSABR trial can be discussed. This way we provide a platform for panel discussions with patients related to clinical trial design.